Joseph Michael Fitzgerald - Oct 7, 2024 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: EVP & Group Pres, Cardiology
Signature: /s/ Susan Thompson, Attorney-in-Fact
Stock symbol: BSX
Transactions as of: Oct 7, 2024
Transactions value $: -$8,806,888
Form type: 4
Date filed: 10/8/2024, 05:48 PM
Previous filing: Aug 29, 2024
Next filing: Nov 26, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BSX	Common Stock	Options Exercise	$1.02M	+59K	+33.47%	$17.26	235K	Oct 7, 2024	Direct	F1
transaction	BSX	Common Stock	Options Exercise	$1.44M	+57.6K	+24.48%	$24.98	293K	Oct 7, 2024	Direct	F1
transaction	BSX	Common Stock	Sale	-$11.3M	-133K	-45.23%	$85.00	160K	Oct 7, 2024	Direct	F1, F2
holding	BSX	Common Stock						4.89K	Oct 7, 2024	By Child	F3

Showing 1 to 4 of 4 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BSX	Stock Option (Right to Buy)	Options Exercise	$0	-59K	-100%	$0.00	0	Oct 7, 2024	Common Stock	59K	$17.26	Direct	F1, F4
transaction	BSX	Stock Option (Right to Buy)	Options Exercise	$0	-57.6K	-100%	$0.00	0	Oct 7, 2024	Common Stock	57.6K	$24.98	Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024.
F2	Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.01, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3	The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
F4	Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
F5	Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant.